PetMed Express Inc. (PETS) - Q2 2025 (Ended Sept 30, 2024) Summary
Business Context and Reporting Period
PetMed Express, Inc. is a leading direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, and veterinary services. The company operates primarily through its websites (PetMeds.com and PetCareRx.com). This report covers the second quarter of fiscal year 2025, ended September 30, 2024. The company is an accelerated filer with a fiscal year-end of March 31.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Sales | $59.6 million | $71.0 million | $127.5 million | $149.2 million |
| Gross Profit | $17.3 million | $20.1 million | $35.3 million | $42.6 million |
| Gross Margin | 29.1% | 28.3% | 27.7% | 28.5% |
| Operating Income | $0.6 million | $0.9 million | $4.9 million | ($1.3 million) |
| Net Income | $2.3 million | $0.7 million | $6.1 million | ($0.4 million) |
| Diluted EPS | $0.11 | $0.03 | $0.29 | ($0.02) |
| Cash & Equivalents | $52.0 million (as of Sept 30, 2024) | |||
| Working Capital | $21.9 million (as of Sept 30, 2024) | |||
| Debt | No debt obligations |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 16.1% year-over-year (YoY) for the quarter and 14.6% for the six months. This was driven by a 13.7% drop in reorder sales (primarily prescription medications) and a 29.4% drop in new order sales due to a strategic reduction in media spend.
- Profitability Improvement: Despite lower sales, Net Income increased significantly ($2.3M vs $0.7M in Q2; $6.1M vs loss of $0.4M YTD). This was largely due to a $7.6 million reversal of stock-based compensation expense related to the departure of the former CEO and CFO, and a favorable income tax benefit.
- Expense Reduction: General and administrative expenses dropped 44.5% YTD, primarily due to the stock compensation reversal. Advertising expenses decreased 16.4% in the quarter, though customer acquisition costs rose to $60 per new customer (from $49) due to less efficient variable marketing spend.
- Inventory Management: Inventory levels decreased significantly from $28.6 million to $13.1 million as part of an SKU rationalization strategy.
Guidance, Outlook, and Risks
- Outlook: Management expects macroeconomic factors (inflation, interest rates) and enterprise cost optimization efforts to continue impacting revenue growth rates for the remainder of fiscal 2025. The company is focusing on operational efficiency and variable cost structures.
- Dividends: The quarterly dividend was suspended indefinitely in October 2023 to focus cash flow on growth initiatives. No dividends were declared in the current period.
- Goodwill Impairment Test: Due to share price decreases and sales declines, the company performed an interim goodwill impairment test. Goodwill was determined not to be impaired, with fair value exceeding carrying value by approximately $44.8 million.
- Internal Control Weaknesses: The company disclosed that disclosure controls and procedures were not effective as of September 30, 2024. Material weaknesses were identified regarding:
- Application of GAAP for sales tax liabilities and executive compensation deductibility (Section 162(m)).
- Valuation of deferred tax assets and goodwill related to the PetCareRx acquisition.
- Information Technology General Controls (ITGCs) regarding user access and change management.
- Legal Proceedings: A class action lawsuit was filed in April 2024 alleging violations of Pennsylvania's Unfair Trade Practices Law regarding "regular" price representations. The company denies liability and cannot estimate potential damages.
Investor Verification Checklist
- Stock Compensation Impact: Verify the sustainability of earnings given the $7.6 million non-cash reversal of stock-based compensation in the current period.
- Revenue Trends: Monitor the continued decline in new customer acquisition and reorder sales to assess the effectiveness of the reduced marketing spend strategy.
- Internal Controls: Review the progress of the remediation plan for the identified material weaknesses in tax accounting and ITGCs, as these pose risks to future financial reporting accuracy.
- Legal Exposure: Track the status of the Pennsylvania class action lawsuit regarding pricing representations.
- Inventory Levels: Confirm that the aggressive inventory reduction does not lead to stockouts or lost sales opportunities.